Stocks:
5,167
ETFs:
2,288
Exchanges:
11
Market Cap:
$62.23T
24h Vol:
$9.26B
Dominance:
MSFT:4.87%
Stocklytics Platform
Instrument logo  ENVB
Enveric Biosciences
ENVB
49 / 100
Penny Stock
$0.88arrow_drop_down6.07%-$0.05

Performance History

Stocklytics logo
Key Stats
Open$0.88
Prev. Close$0.89
EPS-8.09
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
Market Cap6280134.00
PE Ratio-
LOWHIGH
Day Range0.88
0.98
52 Week Range0.64
6.98
Ratios
P/B Ratio3.73
Revenue-
Operating M. %0.00%
Earnings$0.00
Earnings Growth %6.28%
EBITDA Margin %-
ROE %-197.47%
EPS-8.09

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

49vs 54. Market Avg.

All Score 49 / 100 is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

ENVBMARKET
Value5640
Quality3040
Ownership617
Growth5445
Dividends-38
check_circle

Enveric Biosciences's Price discount from all time high of 100% is great compared to market average of 42.03%. This indicates ENVB could be a good value stock.

Financial Forecast

AI Price Prediction

line chart placeholder

Analyst Ratings

info
Analyst ratings for this stock instrument are based on analysts' assumptions and should not be solely relied upon for financial decisions.

Correlated Companies

PRICE$732.20
24H (%)arrow_drop_down1.80%
24H ($)-$13.48
MARKET CAP$695.32B
PRICE$487.29
24H (%)arrow_drop_up0.23%
24H ($)$1.12
MARKET CAP$452.88B
PRICE$148.53
24H (%)arrow_drop_down0.68%
24H ($)-$1.03
MARKET CAP$359.34B
PRICE$127.00
24H (%)arrow_drop_up0.09%
24H ($)$0.12
MARKET CAP$321.39B

About Enveric Biosciences (ENVB)

Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead program is EB-373, an active metabolite of psilocybin, which is in Phase 1 clinical trials for the treatment of anxiety disorders; EVM-301 for treating mental health; and EV104 CBD + Celecoxib conjugate for treating osteoarthritis. The company also developing cannabinoid-infused topical product for the treatment of radiodermatitis; and cannabinoid and COX-2 inhibitor conjugation that is in pre-clinical stage for the treatment of OA/acute pain. Enveric Biosciences, Inc. is headquartered in Naples, Florida.

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Joseph Edward Tucker Ph.D.
Headquarters
Naples
Employees
25
Exchange
NASDAQ
add Enveric Biosciences to watchlist

Keep an eye on Enveric Biosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help
What is Enveric Biosciences's (ENVB) price per share?

The current price per share for Enveric Biosciences (ENVB) is $0.93. The stock has seen a price change of $0.04 recently, indicating a 4.12% change. This reflects the stock's recent market performance and investor sentiment.

help
What is the 52-week high and low for Enveric Biosciences (ENVB)?

For Enveric Biosciences (ENVB), the 52-week high is $6.98, which is 647.32% from the current price. The 52-week low is $0.65, the current price is 43.91% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help
Is Enveric Biosciences (ENVB) a growth stock?

Enveric Biosciences (ENVB) has shown an average price growth of -74.1% over the past three years. It has received a score of -3 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Enveric Biosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help
What is Enveric Biosciences (ENVB) stock price performance year to date (YTD)?

As of the latest data, Enveric Biosciences (ENVB) has a year-to-date price change of -25.87%. Over the past month, the stock has experienced a price change of -11.05%. Over the last three months, the change has been 6.14%. Over the past six months, the figure is -50.32%. Looking at a longer horizon, the five-year price change stands at -99.94%.

help
Is Enveric Biosciences (ENVB) a profitable company?

Enveric Biosciences (ENVB) has a net income of -$17.31M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$16.45M. Furthermore, the EBITDA is -$16.1M.

help
What is the market capitalization of Enveric Biosciences (ENVB)?

Enveric Biosciences (ENVB) has a market capitalization of $6.28M. The average daily trading volume is 139.58K, indicating the stock's liquidity and investor engagement.

News

email

Sign up for our newsletter

Join our exclusive community of over one million investment enthusiasts and receive our free newsletter filled with analysis, news, and updates every weekday.

Approach investments with caution like a driver who slows down on a curvy road.